Heparinless cardiopulmonary bypass revisited: a newer strategy to avoid heparin-related bleeding using dermatan sulfate.
Brister
S J
SJ
Department of Surgery, Hamilton Civic Hospitals, Ontario, Canada.
Buchanan
M R
MR
D000818:Animals; D000925:Anticoagulants / Q000494:pharmacology / Q000627:therapeutic use*; D000990:Antithrombin III / Q000032:analysis / Q000187:drug effects; D016063:Blood Loss, Surgical / Q000517:prevention & control*; D002315:Cardiopulmonary Bypass / Q000295:instrumentation; D003871:Dermatan Sulfate / Q000494:pharmacology / Q000627:therapeutic use*; D005337:Fibrin / Q000032:analysis; D006331:Heart Diseases / Q000209:etiology / Q000473:pathology; D006493:Heparin / Q000009:adverse effects*; D015844:Heparin Cofactor II / Q000187:drug effects; D002542:Intracranial Embolism and Thrombosis / Q000209:etiology / Q000473:pathology; D013249:Sternum / Q000601:surgery; D013499:Surface Properties; D013552:Swine; D013908:Thoracotomy; D013917:Thrombin / Q000037:antagonists & inhibitors; D013927:Thrombosis / Q000209:etiology / Q000473:pathology; D014914:Whole Blood Coagulation Time
D000925:Anticoagulants; D003871:Dermatan Sulfate; D015844:Heparin Cofactor II; D000990:Antithrombin III; D005337:Fibrin; D006493:Heparin; D013917:Thrombin